Melanoma Study Achieves Key Milestone as Bristol's Flagship Treatment Secures Improvement in Survival Rates

Bristol Myers Squibb & Co BMY announced results from the Phase 3 CheckMate -76K trial evaluating Opdivo (nivolumab) in melanoma patients.
Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival (RFS) versus placebo.
Related: Bristol Myers' Deucravacitinib Scores FDA Approval For Plaque Psoriasis.
No new safety signals were observed at the time of the analysis.
CheckMate -76K is part of BMS' development program studying Opdivo and Opdivo-based combinations in earlier stages of cancer, which currently spans seven tumor types.
The company will complete a full evaluation of the CheckMate -76K data and looks forward to sharing the results at an upcoming medical conference.
Price Action: BMY shares are up 1.37% at $71.44 on the last check Thursday.